RedHill Biopharma (RDHL) Total Non-Current Liabilities (2011 - 2025)
RedHill Biopharma's (RDHL) quarterly Total Non-Current Liabilities came in at $1.9 million in Q4 2025, up 268.99% year-over-year from $503000.0 in Q4 2024, and up 271.2% quarter-over-quarter from $500000.0 in Q2 2025.
Powered by 
Analysis
RedHill Biopharma (RDHL) Total Non-Current Liabilities (2011 - 2025) Analysis & Trends
RedHill Biopharma (RDHL) has reported Total Non-Current Liabilities for 15 consecutive years, with $1.9 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities rose 268.99% year-over-year to $1.9 million in Q4 2025; TTM through Dec 2025 was $1.9 million, a 268.99% increase from a year earlier, with the FY2025 full-year figure at $1.9 million, up 268.99% from the prior year.
- Total Non-Current Liabilities was $1.9 million for Q4 2025 at RedHill Biopharma, up from $500000.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $94.9 million in Q2 2021 and troughed at $500000.0 in Q2 2025.
- A 5-year average of $21.0 million and a median of $2.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities plunged 89.86% in 2023 and surged 268.99% in 2025, its largest moves.
- Over 5 years, Total Non-Current Liabilities stood at $83.6 million in 2021, then slumped by 88.26% to $9.8 million in 2022, then sank by 89.86% to $995000.0 in 2023, then sank by 49.45% to $503000.0 in 2024, then surged by 268.99% to $1.9 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $1.9 million (Q4 2025), $500000.0 (Q2 2025), and $503000.0 (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 16.45 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 18.76 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 1.29 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 2.78 Bn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 24.86 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 1.45 Bn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 881.37 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 946.17 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 20.92 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | 1.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1.86 Mn |
| Jun 30, 2025 | 500,000.00 |
| Dec 31, 2024 | 503,000.00 |
| Jun 30, 2024 | 730,000.00 |
| Dec 31, 2023 | 995,000.00 |
| Jun 30, 2023 | 3.38 Mn |
| Dec 31, 2022 | 9.82 Mn |
| Jun 30, 2022 | 13.49 Mn |
| Dec 31, 2021 | 83.62 Mn |
| Jun 30, 2021 | 94.92 Mn |
| Dec 31, 2020 | 93.14 Mn |
| Jun 30, 2020 | 95.91 Mn |
| Dec 31, 2019 | 3.48 Mn |
| Jun 30, 2019 | 3.74 Mn |
| Dec 31, 2018 | 844,000.00 |
| Dec 31, 2017 | 448,000.00 |
| Dec 31, 2016 | 10.45 Mn |
| Sep 30, 2016 | 7.34 Mn |
| Jun 30, 2016 | 6.22 Mn |
| Mar 31, 2016 | 5.56 Mn |